Indication

Extended adjuvant treatment of adult patients with early-Etage hormone receptor positive HER2-overexpressed/amplified breast cancer and who completed adjuvant trastuzumab-based therapy less than one year ago.

Medicine details

Medicine name:
neratinib (Nerlynx)
SMC ID:
SMC2251
Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Publication due date:
11 May 2020
SMC meeting date:
07 April 2020
Patient group submission deadline:
02 March 2020